Rhiannon N. Hardwick

Rhiannon N. Hardwick

Auto-generated profile, based on publicly available information

Rhiannon N. Hardwick

International Consortium for Innovation and Quality in Pharmaceutical Development (IQ)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
DSDavid M. Stresser
David M. Stresser
AKAnna K. Kopec
Anna K. Kopec
PHPhilip Hewitt
Philip Hewitt
RHRhiannon N. Hardwick
Rhiannon N. Hardwick
TVTerry R. Van Vleet
Terry R. Van Vleet
KHKimberly A. Homan
Kimberly A. Homan

10 October 2019 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
RHRhiannon N. Hardwick
Rhiannon N. Hardwick
CBCatherine J. Betts
Catherine J. Betts
JWJessica Whritenour
Jessica Whritenour
RSRadhakrishna Sura
Radhakrishna Sura
MTMaike Thamsen
Maike Thamsen
KFKristin Fabre
Kristin Fabre
Skin is the largest organ of the body and serves as the principle barrier to the environment. Composed of multiple cell types arranged in stratified layers with highly specialized appendages, it serves sensory and immune surveillance roles in addition to its primary mechanical function. Several complex in vitro models of skin (i.e. microphysiological systems (MPS) including but not limited to 3D tissues, organ-on-a-chip, organoids), have been developed and assays validated for regulatory purposes. As such, skin is arguably the most advanced organ with respect to model development and adoption across industries including chemical, cosmetic, and to a somewhat lesser extent, pharmaceutical. Early adoption of complex skin models and associated assays for assessment of irritation and corrosion spurred research into other areas such as sensitization, absorption, phototoxicity, and genotoxicity. Despite such considerable advancements, opportunities remain for immune capabilities, inclusion of appendages such as hair follicles, fluidics, and innervation, among others. Herein, we provide an overview of current complex skin model capabilities and limitations within the drug development scheme, and recommendations for future model development and assay qualification and/or validation with the intent to facilitate wider adoption of use within the pharmaceutical industry.

11 June 2022 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
IRIvan Rusyn
Ivan Rusyn
CSCourtney Sakolish
Courtney Sakolish
YKYuki Kato
Yuki Kato
CSClifford Stephan
Clifford Stephan
LVLeoncio Vergara
Leoncio Vergara
RBRichard A Becker
Richard A Becker
Much has been written and said about the promise and excitement of microphysiological systems, miniature devices that aim to recreate aspects of human physiology on a chip. The rapid explosion of the offerings and persistent publicity placed high expectations on both product manufacturers and regulatory agencies to adopt the data. Inevitably, discussions of where this technology fits in chemical testing paradigms are ongoing. Some end-users became early adopters, whereas others have taken a more cautious approach because of the high cost and uncertainties of their utility. Here, we detail the experience of a public-private collaboration established for testing of diverse microphysiological systems. Collectively, we present a number of considerations on practical aspects of using microphysiological systems in the context of their applications in decision-making. Specifically, future end-users need to be prepared for extensive on-site optimization and have access to a wide range of imaging and other equipment. We reason that cells, related reagents, and the technical skills of the research staff, not the devices themselves, are the most critical determinants of success. Extrapolation from concentration-response effects in microphysiological systems to human blood or oral exposures, difficulties with replicating the whole organ, and long-term functionality remain as critical challenges. Overall, we conclude that it is unlikely that a rodent- or human-equivalent model is achievable through a finite number of microphysiological systems in the near future; therefore, building consensus and promoting the gradual incorporation of these models into tiered approaches for safety assessment and decision-making is the sensible path to wide adoption.

4 February 2022 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
RHRhiannon N Hardwick
Rhiannon N Hardwick
PBPatrick Brassil
Patrick Brassil
IBIlaria Badagnani
Ilaria Badagnani
KPKimberly Perkins
Kimberly Perkins
GOGlenmar P Obedencio
Glenmar P Obedencio
EHEric B Harstad
Eric B Harstad
Izencitinib (TD-1473), an oral, gut-selective pan-Janus kinase (JAK) inhibitor under investigation for treatment of inflammatory bowel diseases, was designed for optimal efficacy in the gastrointestinal tract while minimizing systemic exposures and JAK-related safety findings. The nonclinical safety of izencitinib was evaluated in rat and dog repeat-dose and rat and rabbit reproductive and developmental toxicity studies. Systemic exposures were compared with JAK inhibitory potency to determine effects at or above pharmacologic plasma concentrations (≥1× plasma average plasma concentration [Cave]:JAK 50% inhibitory concentration [IC50] ratio). In rats and dogs, 1000 and 30 mg/kg/day izencitinib, respectively, produced minimal systemic findings (ie, red/white cell changes) and low systemic concentrations (approximately 1× plasma Cave:JAK IC50 ratio) with an 8× nonclinical:clinical systemic area under the curve (AUC) margin compared with exposures at the highest clinically tested dose (300 mg, quaque die, once daily, phase 1 study in healthy volunteers). In dogs, it was possible to attain sufficient systemic exposures to result in immunosuppression characteristic of systemic JAK inhibition, but at high AUC margins (43×) compared with systemic exposures observed at the highest tested dose in humans. No adverse findings were observed in the gastrointestinal tract or systemic tissues. Izencitinib did not affect male or female fertility. Izencitinib did not affect embryonic development in rats and rabbits as commonly reported with systemic JAK inhibition, consistent with low maternal systemic concentrations (2–6× plasma Cave:JAK IC50 ratio, 10–33× nonclinical:clinical AUC margin) and negligible fetal exposures. In conclusion, the izencitinib gut-selective approach resulted in minimal systemic findings in nonclinical species at pharmacologic, clinically relevant systemic exposures, highlighting the impact of organ-selectivity in reducing systemic safety findings.